Logo

American Heart Association

  1
  0


Final ID: 45

Time to Treatment in Intracerebral Hemorrhage Across the United States

Abstract Body: Introduction: Contrary to improved mortality in acute ischemic stroke (AIS), mortality of intracerebral hemorrhage (ICH) remains high. This may be attributable to delays in acute treatments for ICH patients. We aimed to establish the current time to treatment in ICH patients across the U.S., compare this to AIS patients, and assess the impact of treatment times on outcomes.

Methods: This multicenter cross-sectional retrospective study pooled ICH and AIS patients aged ≥ 18 years with admission between January 1, 2017 to December 31, 2022 to acute care hospitals nationwide participating in the Get with the Guidelines-Stroke quality improvement registry. Baseline demographics, clinical variables including time to treatment (antihypertensive agent, hemostatic agent, neurosurgery, thrombolytic or thrombectomy) were abstracted and compared using classical statistics. Logistic regression and time dependent Cox analysis were performed to assess the impact of time to treatment on discharge disposition and mortality in ICH patients.

Results: We identified 3,344 ICH patients (mean (standard deviation) age 66(16) years, 43% female, and 5,386 AIS patients (mean (SD) 69(15) years, 48 % female) across eleven hospital systems. Median door to CT time was significantly longer in ICH compared with AIS patients at 26[12-69] vs14[8-25] minutes.
Median NIHSS for ICH patients was significantly higher (13[5-25]) than AIS patients (10[4-18]). In ICH patients, median[IQR] arrival systolic blood pressure (SBP) was 179[160-205] mm HG and anticoagulation (AC) use was documented in 13.8%. Door to first treatment was 67[32-246] minutes for ICH patients and 55[35-114] minutes for AIS patients. ICH patients had a greater length of stay (7[3-14] days vs 5[2-9] days) and a higher median discharge mRS (4[3-6] vs 3[1-4]), p < 0.01 for all). Controlling for age, gender, race/ethnicity, NIHSS score, door to ED evaluation, prior AC use, arrival SBP and admission INR, the 1,047(31%) patients who were treated within 60 minutes from arrival had a higher likelihood of discharge to home or acute rehab; OR 1.73 95% CI (1.01-2.97). Time to antihypertensive treatment was a significant predictor of time to death with a hazard ratio (HR) of 1.22(1.03-1.45, p= 0.02).

Conclusion: Compared to AIS patients, time to treatment for ICH patients is generally longer. Faster treatment times were associated with better discharge outcomes. These findings emphasize the need for improved time metrics in ICH care.
  • Melmed, Kara  ( NYU Langone Health , New York , New York , United States )
  • Krishnamohan, Prashanth  ( STANFORD UNIVERSITY , Palo Alto , California , United States )
  • Subramaniam, Thanujaa  ( Brown University , Providence , Rhode Island , United States )
  • Stretz, Christoph  ( Brown University , Providence , Rhode Island , United States )
  • Lee, Wen-yu  ( NYU Langone Health , New York , New York , United States )
  • Kuohn, Lindsey  ( NYU Langone Health , New York , New York , United States )
  • Fong, Christine  ( Harborview Medical Center , Seattle , Washington , United States )
  • Houghton, Margaret  ( University of Kansas Health System , Leavenworth , Kansas , United States )
  • Campbell, Alexis  ( MASSACHUSETTS GENERAL HOSPITAL , Lynnfield , Massachusetts , United States )
  • Song, Shlee  ( CEDARS-SINAI MEDICAL CTR , Los Angeles , California , United States )
  • O'phelan, Kristine  ( University of Miami , Neurology , Miami , Florida , United States )
  • Lele, Abhijit  ( Harborview Medical Center , Seattle , Washington , United States )
  • Sheth, Kevin  ( YALE UNIVERSITY SCHOOL OF MEDICINE , New Haven , Connecticut , United States )
  • Venkatasubramanian, Chitra  ( STANFORD STROKE CENTER , Palo Alto , California , United States )
  • Yaghi, Shadi  ( Brown University , Providence , Rhode Island , United States )
  • Mayer, Stephan  ( New York Medical College , Valhalla , New York , United States )
  • Diaz, Ivan  ( NYU Langone Health , New York , New York , United States )
  • Frontera, Jennifer  ( NYU Langone Hospitals , NYC , New York , United States )
  • Ayodele, Mara  ( UCSF Medical Center , San Francisco , California , United States )
  • Goldstein, Joshua  ( MASSACHUSETTS GENERAL HOSPITAL , Lynnfield , Massachusetts , United States )
  • Lackamp, Aaron  ( The University of Kansas , Lenexa , Kansas , United States )
  • Dombrowski, Keith  ( USF , Raleigh , North Carolina , United States )
  • Alkhachroum, Ayham  ( University of Miami , Miami , Florida , United States )
  • Mainali, Shraddha  ( Virginia Commonwealth University , Richmond , Virginia , United States )
  • De Havenon, Adam  ( Yale University , New Haven , Connecticut , United States )
  • Author Disclosures:
    Kara Melmed: DO NOT have relevant financial relationships | Prashanth Krishnamohan: DO have relevant financial relationships ; Advisor:Vitaly Medical:Active (exists now) | Thanujaa Subramaniam: No Answer | Christoph Stretz: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Massachusetts General Hospital/Boston Scientific:Past (completed) | Wen-Yu Lee: DO NOT have relevant financial relationships | Lindsey Kuohn: DO NOT have relevant financial relationships | Christine Fong: DO NOT have relevant financial relationships | Margaret Houghton: DO NOT have relevant financial relationships | Alexis Campbell: DO NOT have relevant financial relationships | Shlee Song: DO have relevant financial relationships ; Advisor:Kandu:Active (exists now) | Kristine O'Phelan: DO NOT have relevant financial relationships | ABHIJIT Lele: DO NOT have relevant financial relationships | Kevin Sheth: DO NOT have relevant financial relationships | Chitra Venkatasubramanian: DO NOT have relevant financial relationships | Shadi Yaghi: DO NOT have relevant financial relationships | Stephan Mayer: DO NOT have relevant financial relationships | Ivan Diaz: No Answer | Jennifer Frontera: DO NOT have relevant financial relationships | Mara Ayodele: DO NOT have relevant financial relationships | Joshua Goldstein: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Consultant:NControl:Past (completed) ; Consultant:Pfizer:Past (completed) ; Individual Stocks/Stock Options:Cayuga:Active (exists now) ; Consultant:Takeda:Active (exists now) ; Consultant:CSL Behring:Past (completed) ; Consultant:Octapharma:Active (exists now) | Aaron LacKamp: DO NOT have relevant financial relationships | Keith Dombrowski: DO have relevant financial relationships ; Consultant:Samsung Neurologica:Active (exists now) | Ayham Alkhachroum: DO NOT have relevant financial relationships | Shraddha Mainali: DO NOT have relevant financial relationships | Adam de Havenon: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH/NINDS:Active (exists now) ; Researcher:UptoDate:Active (exists now) ; Individual Stocks/Stock Options:Certus:Active (exists now) ; Individual Stocks/Stock Options:TitinKM:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):AAN:Active (exists now)
Meeting Info:
Session Info:

Cerebrovascular Systems of Care Oral Abstracts I

Wednesday, 02/05/2025 , 02:00PM - 03:00PM

Oral Abstract Session

More abstracts on this topic:
Early Intensive Blood Pressure Lowering within 6 hours of Intracerebral Hemorrhage Onset is Associated with Improved Functional Outcomes in Larger Trials, but Inconclusive Evidence Overall: A Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials

Rajith Gokul, Erzinger Gabriel, Rizwan Ahmed Aisha, Silva Yasmin, Noll Giovani, Hussain Masaraf, Premraj Lavienraj

Assessment of Limited English Proficiency on Door To Imaging Time

Cort Mark, Sharrief Anjail, Trang Ivan, Nguyen Courtney, Wang Mengxi, Flake-rojas Mariel, Cooksey Gail, Carter Caitlynn, Okpala Munachi, Yamal Jose-miguel

More abstracts from these authors:
Determining Eligible Thrombolysis Candidates for Isolated Dizziness

Wasserstrom Briana, Mallick Dania, Furie Karen, Stretz Christoph, Burton Tina, Perelstein Elizabeth, Khan Farhan, Yaghi Shadi

Con: Andexanet alfa is Preferred over PCC for Reversal of FXa Inhibitor Associated ICH

Yaghi Shadi, Frontera Jennifer, Falcone Guido

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)